Volume : 11, Issue : 10, October – 2024
Title:
CORTICOSTEROIDS: GENERAL KNOWLEDGE FOR ALL HEALTHCARE PROFESSIONALS-UPDATED REVIEW
Authors :
Mousa Saleh E Alhazmi, Bassam Mohammed Tana Almutlaq, Mohammed Mejdl Alruwaili, Naif Shaim Alanazi
Abstract :
Background: Corticosteroids are synthetic analogs of adrenal steroid hormones with potent anti-inflammatory and immunosuppressive properties, widely used across medical specialties. Their therapeutic applications span endocrine disorders, inflammatory conditions, and autoimmune diseases, but their use is complicated by significant adverse effects.
Aim: This review synthesizes current knowledge on corticosteroid pharmacology, clinical applications, adverse effects, contraindications, and monitoring strategies to guide healthcare professionals in optimizing therapy while minimizing risks.
Methods: A comprehensive literature review was conducted, analyzing peer-reviewed articles, clinical guidelines, and pharmacological data on corticosteroid mechanisms, administration routes, toxicity profiles, and monitoring protocols.
Results: Corticosteroids exert effects via genomic and non-genomic pathways, with routes of administration tailored to clinical needs (oral, parenteral, inhaled, topical). Adverse effects—including osteoporosis, HPA axis suppression, diabetes, myopathy, and psychiatric disturbances—are dose- and duration-dependent. Contraindications include systemic fungal infections, uncontrolled diabetes, and live vaccine coadministration. Monitoring requires baseline and periodic assessments of bone density, glucose, adrenal function, and cardiovascular health. Interprofessional collaboration is critical to mitigate risks.
Conclusion: While indispensable in modern medicine, corticosteroids demand judicious use, patient education, and vigilant monitoring to balance efficacy and safety. Future research should focus on safer alternatives and personalized dosing strategies.
Keywords: Corticosteroids, glucocorticoids, adverse effects, HPA axis suppression, osteoporosis, interprofessional care.
Cite This Article:
Please cite this article in press Mousa Saleh E Alhazmi et al., Corticosteroids: General Knowledge For All Healthcare Professionals-Updated Review..,Indo Am. J. P. Sci, 2024; 11 (10).
Number of Downloads : 10
References:
1. Ericson-Neilsen W, Kaye AD. Steroids: pharmacology, complications, and practice delivery issues. Ochsner J. 2014 Summer;14(2):203-7.
2. Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R, Brown JP, Cohen A, Kim H. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013 Aug 15;9(1):30.
3. Ramamoorthy S, Cidlowski JA. Corticosteroids: Mechanisms of Action in Health and Disease. Rheum Dis Clin North Am. 2016 Feb;42(1):15-31, vii.
4. Schäcke H, Döcke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther. 2002 Oct;96(1):23-43.
5. Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol. 2011 Mar 15;335(1):2-13.
6. Streeten DH. Corticosteroid therapy. II. Complications and therapeutic indications. JAMA. 1975 Jun 09;232(10):1046-9.
7. Streeten DH. Corticosteroid therapy. I. Pharmacological properties and principles of corticosteroid use. JAMA. 1975 Jun 02;232(9):944-7.
8. Cain DW, Cidlowski JA. Immune regulation by glucocorticoids. Nat Rev Immunol. 2017 Apr;17(4):233-247.
9. Da Silva JA, Jacobs JW, Kirwan JR, Boers M, Saag KG, Inês LB, de Koning EJ, Buttgereit F, Cutolo M, Capell H, Rau R, Bijlsma JW. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis. 2006 Mar;65(3):285-93.
10. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002 Oct;13(10):777-87.
11. Weinstein RS. Glucocorticoid-induced osteonecrosis. Endocrine. 2012 Apr;41(2):183-90.
12. Fardet L, Cabane J, Lebbé C, Morel P, Flahault A. Incidence and risk factors for corticosteroid-induced lipodystrophy: a prospective study. J Am Acad Dermatol. 2007 Oct;57(4):604-9.
13. Schneiter P, Tappy L. Kinetics of dexamethasone-induced alterations of glucose metabolism in healthy humans. Am J Physiol. 1998 Nov;275(5):E806-13.
14. Moghadam-Kia S, Werth VP. Prevention and treatment of systemic glucocorticoid side effects. Int J Dermatol. 2010 Mar;49(3):239-48.
15. Bolanos SH, Khan DA, Hanczyc M, Bauer MS, Dhanani N, Brown ES. Assessment of mood states in patients receiving long-term corticosteroid therapy and in controls with patient-rated and clinician-rated scales. Ann Allergy Asthma Immunol. 2004 May;92(5):500-5.
16. Kershner P, Wang-Cheng R. Psychiatric side effects of steroid therapy. Psychosomatics. 1989 Spring;30(2):135-9.
17. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med. 2004 Nov 16;141(10):764-70.
18. Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med. 1991 May 01;114(9):735-40.
19. Allen DB, Mullen M, Mullen B. A meta-analysis of the effect of oral and inhaled corticosteroids on growth. J Allergy Clin Immunol. 1994 Jun;93(6):967-76.
20. Kanis JA, Johansson H, Oden A, McCloskey EV. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int. 2011 Mar;22(3):809-16.